Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 11:20 pm
Share
Kukje Pharma Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 32,123.75 million compared to KRW 30,162.65 million a year ago. Net loss was KRW 2,593.81 million compared to net income of KRW 1,456.73 million a year ago. Basic loss per share from continuing operations was KRW 128 compared to basic earnings per share from continuing operations of KRW 72 a year ago. Diluted loss per share from continuing operations was KRW 128 compared to diluted earnings per share from continuing operations of KRW 72 a year ago. Basic loss per share was KRW 128 compared to basic earnings per share of KRW 72 a year ago.
For the nine months, sales was KRW 100,076.36 million compared to KRW 95,654.59 million a year ago. Net loss was KRW 8,026.04 million compared to net income of KRW 4,790.37 million a year ago. Basic loss per share from continuing operations was KRW 396 compared to basic earnings per share from continuing operations of KRW 236 a year ago. Diluted loss per share from continuing operations was KRW 396 compared to diluted earnings per share from continuing operations of KRW 236 a year ago. Basic loss per share was KRW 396 compared to basic earnings per share of KRW 236 a year ago.
Kukje Pharma Co., Ltd, formerly Kukje Pharma Ind. Co., Ltd, is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products are finished products, such as antibiotics, other antibiotics for injection, antifungal and antiviral agents, agents for gastrointestinal tract and liver, muscle relaxants, anti-osteoporotics, corticosteroids, agents for cardiovascular and endocrine systems, ophthalmic agents, remedies for central nervous system (CNS) disorders, remedies for urinary systems, antihistamines, antitussives, cough and cold remedies, non-steroidal anti inflammatory drugs (NSAIDs), antitussive, cough and cold remedies, as well as other over-the-counter (OTC) drugs. It also provides raw materials, such as ceftriaxone sodium sterile, cefuroxime axetil, ceftezole sodium sterile, cefminox sodium sterile, cefuroxime sodium sterile and others.